Consensus AVROBIO, Inc.

Equities

AVRO

US05455M1009

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
1.22 ^USD	+2.52%		+2.52%	-10.29%

03-21	North American Morning Briefing : Investors -2-	DJ
03-14	AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on AVROBIO, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a5d1349b9515d6.7dBIQmc4jLgUmZ9pJ8fiMO1-yq1_NzS1qlFywvbNgwY.2JwiO1Vp-vln6tpbS5CUWdVNiec2Q0zG6GgCk4CB7UqsiiEUDnn592PB-A~e6f5e0893baa348a8f629763243e9a33

Analyst Recommendations on AVROBIO, Inc.

Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	12-18	MT
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	23-07-13	MT
Wedbush Downgrades AVROBIO to Neutral From Outperform on Halted Development of Gene Therapy Programs, Exploring Alternatives; PT is $2	23-07-12	MT
Wedbush Trims AVROBIO's PT to $2 From $4 on Heels of Announced Sale of Cystinosis Gene Therapy Program to Novartis, Keeps Outperform Rating	23-05-22	MT
Mizuho Adjusts Price Target on AVROBIO to $5 From $6, Keeps Buy Rating	23-03-24	MT
BTIG Upgrades AVROBIO to Buy From Neutral, Price Target is $4	22-12-08	MT
Needham Adjusts AVROBIO's Price Target to $6 from $8, Keeps Buy Rating	22-05-17	MT
Barclays Adjusts AVROBIO's Price Target to $4 from $6, Keeps Overweight Rating	22-05-11	MT
Morgan Stanley Adjusts AVROBIO's Price Target to $2 From $3, Maintains Equalweight Rating	22-02-01	MT
Mizuho Adjusts AVROBIO's Price Target to $6 from $28, Keeps Buy Rating	22-01-06	MT
Morgan Stanley Adjusts Price Target on AVROBIO to $3 From $7, Maintains Equal-Weight Rating	22-01-05	MT
Needham Adjusts AVROBIO's Price Target to $8 From $28, Reiterates Buy Rating	22-01-05	MT
BTIG Downgrades AVROBIO to Neutral From Buy	22-01-05	MT
Barclays Adjusts AVROBIO's Price Target to $6 From $22, Reiterates Overweight Rating	22-01-05	MT
Wedbush Lowers PT for AVROBIO to $14 From $30 As Company 'Deprioritizes' Fabry Disease Program, Maintains Outperform Rating	22-01-04	MT
Morgan Stanley Downgrades AVROBIO to Equal-Weight From Overweight, Adjusts Price Target to $7 From $24	21-11-19	MT
AVROBIO : Morgan Stanley Adjusts AVROBIO's Price Target to $25 from $27, Keeps Overweight Rating	21-10-12	MT
AVROBIO : Morgan Stanley Adjusts Price Target on AVROBIO to $29 From $31, Maintains Overweight Rating	21-07-16	MT
AVROBIO : BTIG Starts AVROBIO at Buy With $23 Price Target	21-06-15	MT
AVROBIO : Needham Starts AVROBIO at Buy With $28 Price Target	21-05-27	MT
AVROBIO : Morgan Stanley Adjusts Price Target on AVROBIO to $31 From $34, Maintains Overweight Rating	21-05-14	MT
AVROBIO : Mizuho Securities Adjusts AVROBIO's Price Target to $28 From $43, Maintains Buy Rating	21-05-04	MT
AVROBIO : Wedbush Cuts AVROBIO's Price Target to $30 From $40 on Adjusted Fabry Program Timeline; Outperform Rating Kept	21-05-04	MT
AVROBIO : SVB Leerink Adjusts AVROBIO Price Target to $10 From $18, Maintains Market Perform Rating	21-05-03	MT
AVROBIO : Barclays Starts Avrobio at Overweight With $23 Price Target	21-03-09	MT